Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  


Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 

Bladder Cancer Advocacy Network (BCAN)

BETHESDA, MD – The Bladder Cancer Advocacy Network (BCAN) is seeking applicants for the 2015 Bladder Cancer Research Innovation Award. The award is generously funded by the James Family Foundation in conjunction with Partner Fund Management. The research program will award one $300,000 two-year grant to an experienced investigator who will break new ground in the field of bladder cancer. The application process is open and letters of intent are due by January 14, 2015.

The Bladder Cancer Research Innovation Award was established in 2014 to support exceptionally novel and creative projects with great potential to produce breakthroughs in the management of bladder cancer. Proposals will be accepted for creative ideas and innovative approaches that have direct application and relevance to bladder cancer.

For more information, go to the Bladder Cancer Advocacy website or contact BCAN at 301-215-9099.

 
New Facilities and Administrative (F&A) Rate for Use in Proposals

Negotiations with the Department of Health and Human Services (DHHS) regarding the University’s F&A rates have concluded. DHHS has approved a (3) three year F&A rate of 58.5% for CWRU, which is a 1.5 percentage point change from our previous rate of 57%. This rate will be effective through June 2016.

The new F&A rate should be used when preparing proposal budgets for awards with an anticipated start date of July 1, 2013 or after.

Read the full notice of this change at: https://ora.ra.cwru.edu/research/docs/2012.10.08_Facilities_and_Administrative_rate.pdf.

 
William T. Grant Foundation

The William T. Grant Foundation's Distinguished Fellows Program is designed to increase the supply of, demand for, and use of high-quality research in the service of improved youth outcomes. To accomplish its goals, the program gives influential mid-career researchers the opportunity to immerse themselves in practice or policy settings and gives influential practitioners and policy makers the opportunity to work in research settings.

To that end, the program encourages mid-career researchers to submit proposals that are designed to deepen their understanding of policy processes and practice settings. The program also invites policy makers and practitioners to propose projects that will enhance their capacities to recognize and use high-quality research.

Proposed fellowships must fit the Grant Foundation's research interests. The foundation currently supports research to understand and improve the everyday settings of youth in the United States. Specifically, the foundation funds studies that enhance the understanding of how youth settings work, how they affect youth development, and how they can be improved; and when, how, and under what conditions research evidence is used in policy and practice that affect youth, and how its use can be improved.

Letters of Inquiry must be received no later than January 6, 2015. Upon review, selected applicants will be invited to submit full applications.

The 2014-15 Distinguished Fellows Application Guide, which includes a complete description of the program, eligibility guidelines, and application instructions, is available at the William T. Grant Foundation website.

 
The Ohio Clinical Trial Collaborative (OCTC)

The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.

The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.

Review the OCTC working website at: http://ohioclintrials.org.

Contact Joe Peter at 216-702-5314 for more information.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.